Ronald Lieberman
Overview
Explore the profile of Ronald Lieberman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waller C, Vynnychenko I, Bondarenko I, Shparyk Y, Hodge J, Freeman A, et al.
Clin Lung Cancer
. 2014 Dec;
16(2):92-9.
PMID: 25458558
Introduction: New treatment options are needed for second-line therapy in patients with NSCLC. Patients And Methods: This was a phase Ib/II study in patients with nonsquamous NSCLC in whom 1...
2.
Rick Turner J, Panicker G, Karnad D, Cabell C, Lieberman R, Kothari S
Am J Ther
. 2014 Jan;
21(6):512-22.
PMID: 24451296
Assessments of cardiac and cardiovascular toxicity are prominent components of drug safety endeavors during drug development and clinical practice. Oncologic drugs bring several challenges to both domains. First, during drug...
3.
4.
5.
6.
7.
Simoneau A, Gerner E, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, et al.
Cancer Epidemiol Biomarkers Prev
. 2008 Feb;
17(2):292-9.
PMID: 18268112
Background: Prostate cancer is a major health issue, and prevention of prostate cancer and/or its progression will yield benefits for men. Difluoromethylornithine (DFMO) is an antiproliferative agent, inhibiting ornithine decarboxylase,...
8.
Seren S, Lieberman R, Bayraktar U, Heath E, Sahin K, Andic F, et al.
Am J Ther
. 2008 Jan;
15(1):66-81.
PMID: 18223356
Dietary intake of lycopene is inversely associated with the risk of many cancers. Preclinical studies show that lycopene has potent in vitro and in vivo antitumor effects, suggesting potential preventive...
9.
Marshall J, Sakr W, Wood D, Berry D, Tangen C, Parker F, et al.
Cancer Epidemiol Biomarkers Prev
. 2006 Aug;
15(8):1479-84.
PMID: 16896036
High-grade prostatic intraepithelial neoplasia (HGPIN) is generally regarded as a premalignant lesion that progresses toward prostate cancer. In light of the significant sequelae of prostate cancer treatment, prevention is desirable,...
10.
Jin Y, Iwata K, Belldegrun A, Figlin R, Pantuck A, Zhang Z, et al.
Mol Cancer Ther
. 2006 Aug;
5(7):1754-63.
PMID: 16891461
Alteration of actin remodeling is a marker of malignant-associated field defect and a potential surrogate biomarker for chemoprevention trials. We tested erlotinib, a specific tyrosine kinase inhibitor of epidermal growth...